In recurrent/metastatic (R/M) setting, median overall survival (OS) is about 12 months with chemotherapy alone in first line with very few options available for second  line.

A retrospective study was carried out from a single tertiary centre in India where medical records of all patients with R/M cervical cancer from 1st March 2020 to 30th June 2023 were accessed. As far as nivolumab dosing is concerned, median dosing being administered was 0.84mg/kg for 14 days. Distribution-wise, 16 patients (80%) received >0.6mg/kg for 14 days and 4 patients (20%) patients received <0.6mg/kg 4 (20%). As far as line of treatment distribution is concerned, 10 patients received first-line treatment, 8 patients were administered second-line treatment, third-line treatment was given to 2 patients.

Responses were seen in 6 patients (30%), 4 patients (20%) had a complete response, whereas, 2 patients (10%) had partial response. Median PFS was found to be 7.97 months and median OS was observed to be 15 months. As far as safety is concerned, nine patients, constituting 45% of the study participants, experienced treatment-related adverse events (TRAE). Among them, five individuals, equivalent to 25%, encountered Grade III TRAE. Notably, there were no instances of Grade IV or V adverse events documented.

Conclusion

While cervical cancer rates have diminished in developed nations, it persists as a prevalent malignancy among women in many low- and middle-income countries. In the recurrent/metastatic (R/M) context, chemotherapy alone yields a median overall survival (OS) of approximately 12 months in the first line, with limited options available for the second line. The introduction of checkpoint inhibitors has enhanced survival prospects. In the case of recurrent/metastatic cervical cancer, the use of low-dose Nivolumab has shown promise in improving outcomes with manageable side effects. This not only holds the potential to reduce financial burdens but also enhances accessibility, particularly in regions with a higher prevalence of this disease and economic constraints.

Reference reports by DelveInsight for more in-depth analysis and key coverage - 

• Cervical Cancer Market Insight, Epidemiology, And Market Forecast
• Ovarian Cancer Market Insight, Epidemiology, And Market Forecast